

HENRY HE

Fangda Partners

+86 21 2208 1185

henry.he@fangdalaw.com



PRACTICE AREAS

MR. HE SPECIALIZES IN CROSS-BORDER TRANSACTIONS INVOLVING COMPLEX BUSINESS, INTELLECTUAL PROPERTY, OPERATIONAL AND LEGAL ISSUES, INCLUDING STRATEGIC PARTNERSHIPS, PRODUCT AND TECHNOLOGY LICENSING (IN/OUT), ASSET ACQUISITIONS AND DIVESTITURES, PLATFORM DISCOVERY AND OPTION DEALS. ADDITIONALLY, MR. HE COUNSELS LIFE SCIENCES CLIENTS ON DAY-TO-DAY OPERATIONAL MATTERS INVOLVING CLINICAL TRIALS, REGULATORY COMPLIANCE, DRUG SUPPLY AND PROMOTION, RESEARCH AND COMMERCIALIZATION COLLABORATIONS.

REPRESENTATIVE MATTERS AND CASES

Licensing and Corporate Partnering

- Represented Kanghua (300841.SZ) in granting HilleVax (HLVX.Nasdaq) the exclusive rights to develop, manufacture and commercialize Kanghua's hexavalent virus-like particle (VLP) vaccine candidate for norovirus in the ex-Greater China territory.
- Represented TJ Bio to enter into a strategic collaboration with Sanofi for developing, manufacturing and commercializing the globally innovative asset CD73 monoclonal antibody (Ullimab) in Greater China.
- Represented LaNova Medicines in granting MSD an exclusive global to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody, including handling upstream licensing arrangements, under which LaNova will receive an upfront payment of US\$588 million and is eligible to receive up to US\$2.7 billion in milestone payments associated with the progress of LM-299 across multiple indications.

- Represented Hengrui Pharmaceuticals (600276.SH) in its out-licensing partnership with Aiolos Bio with respect to the exploitation of Hengrui's innovative anti-TSLP monoclonal antibody (SHR-1905) in ex-Greater China territory.
- Represented CStone Pharmaceuticals on entering into the Asset Purchase Agreement and the Transition Plan Agreement with Les Laboratoires Servier pursuant to which CStone sold and Servier acquired the TIBSOVO® (Ivosidenib, IDH1 inhibitor) business and any goodwill thereof, including the transferred assets, in Greater China and Singapore.
- Represented Bao Pharmaceutical and its wholly-owned subsidiary Centergene Pharmaceuticals to enter into a Licensing Agreement with Organon for exploiting the innovative investigational asset in assisted reproductive technology (ART), SJ02, a long-acting FSH in BLA Process in China Mainland.
- Represented CSPC's wholly-owned subsidiary Shanghai JMT-BIO to enter into an exclusive license agreement with Jiangsu Alphamab for developing and commercializing JSKN003 (a biparatopic HER2-targeting antibody-drug conjugate/ADC) in Mainland China, with upfront payment plus near-term development milestones amounting to approx. US\$100 million.
- Represented CStone Pharmaceuticals in its strategic out-licensing partnership with Ewopharma for commercialization of Sugemalimab (anti-PD-L1 mAb) in Switzerland and nearly 20 Central & Eastern European countries.
- Represented CStone Pharmaceuticals in its strategic out-licensing partnership with Pharmalink (a United Arab Emirates headquartered pharmaceutical company) for commercialization of Sugemalimab (anti-PD-L1 mAb) in the Middle East and North Africa countries.
- Represented Sanegene Bio on its strategic collaboration with Huadong Medicine (0963.SZ) with respect to the siRNA drug development for chronic metabolic diseases.
- Represented CStone Pharmaceuticals in out-licensing of exclusive commercialization right related to anti-PD-1 monoclonal antibody (nofazinlimab) in mainland China to 3SBio Inc.
- Represented TargetRx in an exclusive commercialization transaction with Simcere Zaiming with respect to its clinical-stage anti-tumor candidate drug, ALK/ROS1 dual receptor tyrosine kinase inhibitor (TGRX-326) in mainland China, with an upfront payment exceeding US\$20 million.
- Represented MingMed Biotech in its out-licensing partnership with Elanco Animal Health with respect to its JAK small molecule inhibitor for companion

animals in Greater China .

- Represented AstraZeneca in its Clinical Collaboration Agreement with Ascentage Pharma (6855.HK) to jointly conduct a registrational phase III clinical trial of the Bcl-2 inhibitor APG-2575 in combination with AstraZeneca's BTK inhibitor CALQUENCE®.
- Represented UCB on its strategic collaboration with BioRay with respect to the exclusive commercialization of IL-17A and IL-17F inhibitor Bimzelx® (bimekizumab) in China.
- Represented Anheart Therapeutics in granting an exclusive commercialization right with respect to Anheart's lead drug candidate Taletrectinib to Innovent for PRC market and to Nippon Kayaku, a Japanese listed company, for Japan market, respectively.
- Represented AstraZeneca in a co-promotion collaboration with Daiichi Sankyo for the antibody conjugated product DS8201 in the Chinese market according to a global licensing agreement for such product.
- Advised on the multi-faceted strategic collaboration with Pfizer Corp. including a US\$200 million share sale, on (i) PD-L1 monoclonal antibody's China commercialization and (ii) subsequent co-development of Pfizer pipeline assets (including Lorlatinib) and potential joint in-license.
- Represented CStone Pharmaceuticals in granting an exclusive commercial promotion right to Allist (688578.SH), with respect to its approved RET inhibitor Gavreto® (Pralsetinib) in mainland China.
- Advised on the exclusive collaboration and license agreement with LegoChem Biosciences Inc. to develop, manufacture and commercialize LCB71 (ROR1 ADC) for entire world excluding Korea.
- Represented CStone Pharmaceuticals on the out-licensing of CTLA-4 mAb (CS1002)'s development and commercialization rights in Greater China to Hengrui Pharmaceuticals (600276.SH).
- Represented CStone Pharmaceuticals on China MAH transfer for GAVRETO® (Pralsetinib) partnering with Roche and Blueprint on drug supply, manufacturing technology transfer, global clinical development and regulatory matters.
- Advised on the exclusive collaboration and license agreement with Blueprint Medicines Corporation to develop, manufacture and commercialize Avapritinib (KIT/PDGFR4 inhibitor), Fisogatinib (FGFR4 inhibitor) and Pralsetinib (RET inhibitor) in mainland China, Hong Kong, Macau and Taiwan.

- Representing various multinational and domestic life sciences clients including AstraZeneca, Biogen, Boehringer Ingelheim, Bii Biosciences, CStone Pharmaceuticals, Everest Medicines, Hasten Pharmaceuticals, Hengrui Pharmaceuticals, IASO, Insilico Medicine, Laekna Therapeutics, Legend Biotech, MSD, Novartis AG, Roche Pharmaceuticals, Sanogene Bio, UCB, Vera Therapeutics, WuXi AppTec, and Zai Lab, on regulatory advisory and compliance matters arising from day-to-day operations, e.g., research and development projects, clinical trials, HGR (human genetic resources) matters, marketing authorization, drug product supply, distribution, advertising and promotion.

Merger & Acquisitions, Venture Capital and Emerging Companies

- Represented AnHeart Therapeutics in Nuvation Bio (NUVB, NYSE)'s acquisition of AnHeart Therapeutics in an all-stock transaction.
- Represented Kyowa Kirin in its business restructuring of the APAC region through a serial transactions of transferring all rights and interests of Kyowa Kirin China to Hong Kong WinHealth Pharma Group ("WinHealth") and granting a license to WinHealth to commercialize and manufacture five original branded commercial-stage drugs in China and to commercialize two global products in China.
- Represented CStone Pharmaceuticals on Series B financing, pre-IPO restructuring, licensing, early-stage collaboration and offshore/onshore ESOP-related matters.
- Represented Synvida Bio in its series A financing, with an aggregate fundraising amount of approx. RMB200 million, led by Longpan Investment and Shanghai Healthcare Capital (SHC).
- Represented Eight Roads Ventures as the lead investor in its equity investment in the Series A financing of New Trials Medical Technology with the aggregate fundraising size over RMB100million.
- Represented Qiming Ventures and BioTrack Capital as the lead investors in its equity investment in the Series C financing of Bioheng Therapeutics (a clinical-stage biotech focusing on CAR-T therapies).
- Represented Shanghai Healthcare Capital in its investment as lead investor in Series B+ financing of Hexaell Biotech (a clinical-stage biotech focusing on developing novel cell therapies and regenerative medicines for severe liver diseases) with an aggregate fundraising exceeding RMB200 million.
- Represented a China biotech company in its joint venture collaboration with a leading Hong Kong listed pharmaceutical company with respect to distribution and commercialization of certain novel pharmaceutical drugs in

China.

- Represented BioBay in its forming a joint venture, Suqiao Pharma (an one-stop CDMO service provider) with C-Bridge Capital in Suzhou.
- Represented various venture capital funds including Eight Roads Ventures, BioTrack Capital, Shanghai Healthcare Capital, OrbiMed, GGV, Qiming Ventures, Matrix China Partners, Decheng Capital in investments/exit transactions across life science, healthcare, e-commerce, financial services, telecommunication and education sectors.
- Represented various emerging growth companies including AlphaMab Oncology, Curative Medical, Genebox, ABM Therapeutic, Quantifeed, Cashshield, Carousell, Gshopper, Yamibuy, Hycor on equity financings (covering series seed through pre-IPO round), restructuring and asset acquisitions.

OTHER INFORMATION

Education

- East China University of Political Sciences and Law, LL.B; LL.M
- University of Wisconsin-Madison, LL.M

Professional Qualification

- Admitted to practice in Massachusetts
- Admitted to practice in PRC

Work Language

- Mandarin
- English

Publications

- Co-author, "Encountering and Anchoring Opportunities in an Era of Uncertainty: Exploring the Trends and Core Risks of Mergers and Acquisitions of Chinese Biotech Companies", Legal 500 (September 2024)
- www.legal500.com/firms/30805-fangda-partners/c-china/focus-on/encountering-and-anchoring-opportunities-in-an-era-of-uncertainty-exploring-the-trends-and-core-risks-of-mergers-and-acquisitions-of-chinese-biotech-companies
- Co-author, "China life sciences: Transaction insights and notable industry

trends", Legal 500 (February 2024)

- www.legal500.com/fivehundred-magazine/life-sciences/china-life-sciences-transaction-insights-and-notable-industry-trends
- Co-author, "Life Sciences Yearbook 2024: China life sciences Q&A ", Legal 500 (Feb 2024)
- www.legal500.com/fivehundred-magazine/life-sciences/qa-fangda-partners

Professional Background

Mr. He joined Fangda as a partner in 2023. Prior to joining the firm, Mr. He worked as the Board Secretary, Associate Vice President and General Counsel at a well-renowned public biopharmaceutical company. Before moving in-house, Mr. He had worked at two reputable international law firms for many years, representing venture capital funds, emerging companies and multinational corporations with exposure to early-stage financing and pre-IPO restructuring, licensing, venture capital, offshore/onshore ESOP matters and corporate M&A.